---
title: Mandatory notification of trade
description: Mandatory notification of trade Moss, 30 November 2021
---

Moss, 30 November 2021

Reference is made to the annual general meeting 4 May 2021 where a statement of  
remuneration to key personnel was given. In accordance with this statement the  
board of Gentian Diagnostics ASA has allocated a total of 165,674 options to key  
employees under the existing option program.

The following number of options have been allocated to primary insiders of  
Gentian Diagnostics ASA:

Njaal Kind, Group Chief Financial Officer: 40,674 options. Following the  
allocations Mr. Kind hold 21,125 shares and 155,670 options in the Company.

Erling Sundrehagen, Chief Scientific Officer: 20,000 options. Following the  
allocation Mr. Sundrehagen and related parties hold 184,083 shares and 120,000  
options in the Company.

Torsten Knüttel, Vice President R&D: 20,000 options. Following the allocation  
Mr. Knüttel hold 1,125 shares and 30,000 options in the Company.

Jack Andreassen, Vice President Business Development: 2,500 options. Following  
the allocation Mr. Andreassen hold 4,385 shares and 22,500 options in the  
Company.

Markus Jaquemar, Vice President Sales and Marketing: 2,500 options. Following  
the allocation Mr. Jaquemar holds 22,500 options in the Company.

Attached is the notifications of the transactions pursuant to the market abuse  
regulation article 19.

The exercise price for the options granted is NOK 72.60 being the average  
volume-weighted share price on the Oslo Stock Exchange for the past 10 trading  
days prior to 24 November. The right to exercise the options is vested over a  
period of 3 years, with 1/3 of the options vesting by the end of each year as  
follows: (i) 1/3 of the options granted, no earlier than 2 years after the  
allocation date (ii) 1/3 of the options granted, no earlier than 3 years after  
the allocation date (iii) 1/3 of the options granted, no earlier than 4 years  
after the allocation date.

For further information, please contact:

Njaal Kind  
CFO, Gentian Diagnostics  
E-mail: [njaal.kind@gentian.no](mailto:njaal.kind@gentian.no)   
Cell Phone. +47 919 06 525

This information is subject to the disclosure requirements pursuant to the  
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading  
Act.

**More information:**  
[Access the news on Oslo Bors NewsWeb site](https://newsweb.oslobors.no/message/548211)

### You may also read

[Jul 02, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1#)

##### [Gentian Diagnostics: Invitation to presentation of second quarter results](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

Gentian Diagnostics ASA will present its second quarter 2026 results on 9 July 2026 at 09.00 CEST. The..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

[Jun 24, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1#)

##### [ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

Amsterdam / Moss, 24 June 2026 ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

[May 29, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1#)

##### [Mandatory notification of trade](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)

Moss, 29 May 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)